VIM and breast neoplasm: With a similar approach, we have treated MCF-7 cells where the low level of TG2 can be up-modulated by Dox [21,22] and MDA-MB-231 cells showing high basal levels of TG2 with the NC9 inhibitor and investigated the effects on motility, revealing an unprecedented role of TG2 in interacting with vimentin in breast tumor cells.